Reckitt Benckiser has upgraded its expected revenue for its core brands this year, following the implementation of a ...

How political red tape and a drug company’s thirst for profits limited the reach of a drug that experts believe could have ...

The stock traded 9% higher after the company’s core business posted revenue growth ahead of consensus expectations.

Our writer reckons these 10 FTSE 100 shares could potentially be around for a long time yet. What might that mean from an ...

We go inside Reckitt’s real-world rollout of agentic AI with Empathy Lab – and explore why marketers need to stop waiting and ...

Reckitt Benckiser has a lot of attractive peers, and many of them are trading at much lower. The company's primary peers ...

Reckitt, known for products like Durex and Lysol, surpassed expectations with a 1.9% rise in second-quarter net sales, driven by emerging markets. The company increased its 2025 revenue growth ...

Reckitt currently trades at a share price of around £64 (approximately $16 per ADR). This translates to a price-to-sales ratio of 3.4, slightly lower than the ten-year average multiple of 3.7.

Consumer goods giant Reckitt Benckiser RKT-0.04%decrease; red down pointing triangle isn’t exactly in limbo, even as it awaits a new chief executive. The maker of Lysol and Clearasil posted ...

Reckitt , maker of Dettol and Lysol cleaning products, on Wednesday missed third-quarter like-for-like sales expectations as volumes declined, but said it would start a 1 billion pound ($1.2 ...

Reckitt Benckiser is pulling Suboxone tablets, which lost patent protection, from the US market, claiming children can be accidentally harmed, but won't do so for a few months. Meanwhile, Reckitt ...